STROBE Statement—Checklist of items that should be included in reports of ***Observational studies***

	Item No	Recommendation
Title and abstract ***Included in title page and in abstract (pg 1, 4)***	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale ***Included in the introduction (pg 6)***	2	Explain the scientific background and rationale for the investigation being reported
Objectives ***Included in the introduction (pg 6)***	3	State specific objectives, including any prepecified hypotheses
Methods		
Study design ***Included under method section –pg 7***	4	Present key elements of study design early in the paper
Setting ***Included under method section –pg 7***	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants ***Included under method section –pg 7***	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants *b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case
Variables ***Included under the sections of data collection, Identification of children with FAPDs, Asthma and Computation of HRQoL (pg 7-8)***	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement ***Included under the sections of data collection, Identification of children with FAPDs, Asthma and Computation of HRQoL (pg 7-8)***	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias ***Included under the section of data collection (pg-8)***	9	Describe any efforts to address potential sources of bias
Study size ***Included under the sample size calculation –(pg 10)***	10	Explain how the study size was arrived at

Quantitative variables ***Included under the sections of Computation of HRQoL and section of statistical analysis (pg 8)***	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods ***Included under the section of statistical analysis (pg 9)***	12	(*a*) Describe all statistical methods, including those used to control for confounding
		(*b*) Describe any methods used to examine subgroups and interactions
		(*c*) Explain how missing data were addressed
		d) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy
		(*e*) Describe any sensitivity analyses
Results		
Participants ***Included under section of result (pg -10)***	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data ***Included under section of result (pg -10)***	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) *Cohort study*—Summarize follow-up time (eg, average and total amount)
Outcome data ***Included under sections of results (Pg- 10-11), Association between asthma and FAPDs (Table 1 – pg 25), Gastrointestinal symptoms among asthmatics (Table 3 – pg 27)***	15*	*Cohort study*—Report numbers of outcome events or summary measures over time *Case-control study*—Report numbers in each exposure category, or summary measures of exposure *Cross-sectional study*—Report numbers of outcome events or summary measures
Main results ***Included under sections of Association between asthma and FAPDs – pg 10 (Table 1 –pg 25, Table 2 – pg 26)***	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(*b*) Report category boundaries when continuous variables were categorized
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses ***Included under section of HRQoL among affected***	17	Report other analyses done—eg analyses of subgroups

adolescents (pg 10,11) – One way ANOVA was used to compare quality of life between groups (Table 4 – pg 28)		and interactions, and sensitivity analyses
Discussion		
Key results ***Included under section of discussion (pg- 12)***	18	Summarise key results with reference to study objectives
Limitations ***Included under section of discussion (pg- 16)***	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation ***Included under section of discussion (pg- 12-16)***	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability ***Included under section of discussion (pg- 16,17)***	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding ***Self funding by first author***	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.